Structure

InChI Key RONZAEMNMFQXRA-UHFFFAOYSA-N
Smiles CN1CCN2c3ncccc3Cc3ccccc3C2C1
InChI
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C17H19N3
Molecular Weight 265.36
AlogP 2.48
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 0.0
Polar Surface Area 19.37
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 20.0

Bioactivity

Mechanism of Action Action Reference
Adrenergic receptor alpha-2 antagonist ANTAGONIST DailyMed
Protein: Adrenergic receptor alpha-2

Description: Alpha-2A adrenergic receptor

Organism : Homo sapiens

P08913 ENSG00000150594
Protein: Adrenergic receptor alpha-2

Description: Alpha-2B adrenergic receptor

Organism : Homo sapiens

P18089 ENSG00000274286
Protein: Adrenergic receptor alpha-2

Description: Alpha-2C adrenergic receptor

Organism : Homo sapiens

P18825 ENSG00000184160
Protein: Serotonin 2a (5-HT2a) receptor

Description: 5-hydroxytryptamine receptor 2A

Organism : Homo sapiens

P28223 ENSG00000102468
Protein: Serotonin 2c (5-HT2c) receptor

Description: 5-hydroxytryptamine receptor 2C

Organism : Homo sapiens

P28335 ENSG00000147246
Assay Description Organism Bioactivity Reference
The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT None 18.0 nM
Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes None 14.8 nM
The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin None 2.0 nM
The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine None 5.5 nM
Binding affinity at human Alpha-2B adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement. None 223.87 nM
Binding affinity at human Alpha-2A adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement. None 85.11 nM
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement. None 199.53 nM
The binding affinity at the Dopamine receptor D4 determined using [3H]YM-09151-2 None 25.0 nM
The binding affinity at the Dopamine receptor D3 determined using [3H]spiperone None 20.0 nM
The binding affinity at the Histamine H1 receptor determined using [3H]pyrilamine Cavia porcellus 5.1 nM
The binding affinity at the Norepinephrine transporter reuptake sites determined using competition binding assay None 260.0 nM
The binding affinity at the 5-HT reuptake sites determined using competition binding assay None 100.0 nM
Inhibition of [3H]rauwolscine binding to Alpha-2A adrenergic receptor Homo sapiens 20.0 nM
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor Homo sapiens 18.0 nM
Inhibition of [3H]prazosin binding to rat Alpha-1 adrenergic receptor Rattus norvegicus 608.0 nM
Inhibition of [125I]R91150 binding to human 5-hydroxytryptamine 2A receptor Homo sapiens 69.0 nM
Inhibition of [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor Homo sapiens 39.0 nM
Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor Homo sapiens 1.6 nM
Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 7 receptor Homo sapiens 265.0 nM
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) Staphylococcus aureus subsp. aureus -16.68 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) Escherichia coli -1.97 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) Klebsiella pneumoniae 5.61 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) Pseudomonas aeruginosa -7.46 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 Acinetobacter baumannii 8.49 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 Candida albicans 4.27 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) Cryptococcus neoformans 3.57 %
Binding affinity to human 5HT1A receptor Homo sapiens 18.0 nM
Binding affinity to human 5HT2A receptor Homo sapiens 8.2 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 8.32 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.18 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.18 %

Related Entries

Environmental Exposure

Countries
Croatia
Czech Republic
Germany
Hungary
Romania
Serbia
Slovakia
Slovenia

Cross References

Resources Reference
ChEBI 6950
ChEMBL CHEMBL654
DrugBank DB00370
DrugCentral 1816
FDA SRS A051Q2099Q
Human Metabolome Database HMDB0014514
Guide to Pharmacology 7241
KEGG C07570
PharmGKB PA450522
PubChem 4205
SureChEMBL SCHEMBL35408
ZINC ZINC19702119